Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $8.00

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $8.00.

Several equities research analysts recently commented on MIST shares. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Monday, December 15th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Finally, Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $2.05 on Wednesday. The firm has a market cap of $174.60 million, a price-to-earnings ratio of -2.50 and a beta of 0.44. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. The business has a fifty day simple moving average of $2.25 and a 200 day simple moving average of $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. As a group, sell-side analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Joseph Oliveto sold 43,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00. Following the completion of the sale, the chief executive officer owned 303,721 shares in the company, valued at approximately $683,372.25. This represents a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sapient Capital LLC bought a new stake in Milestone Pharmaceuticals during the third quarter worth approximately $25,000. Bay Rivers Group acquired a new stake in shares of Milestone Pharmaceuticals in the second quarter worth $28,000. Bank of America Corp DE lifted its stake in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after buying an additional 16,044 shares during the last quarter. Stephenson & Company Inc. bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth $40,000. Finally, Creative Planning grew its stake in Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares during the last quarter. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.